U-M Institutional Biosafety Committee
Minutes
Approved at the February 20, 2026, IBC Meeting

Meeting Information:

Date: Friday, January 16, 2026
Time: 1:15-2:30 p.m.
Location: NCRC Building 520, Room 1122

Voting Members Present: Matt Chapman, Wanlu Du, Chris Fenno, Huira Kopera, Joyce Lai, Tom Lanigan, Daniel Lawrence, Patrick Lester, Akira Ono, Alex Rickard, Jackie Shields, Andrew Tai, Fei Wen, Christiane Wobus (Chair)

Voting Members Absent: Pamela Bennett-Baker, Sheya Jones, Stephen Rapundalo, John Thomas

Alternate Members Present: Janet Follo (alt. for Jones)

IBC Staff Members Present: Jen Harley, Michael Santiago-Castro, Alicia Trombley

Guests Present: Carolyn Kuenz, Eric Robertson, Nicoleen Boyle, Kathy Ignatoski, Jonah Lee, Pat Ward, Sarah Lawson

The meeting was called to order at: 1:15 p.m.
The meeting was adjourned at: 1:42 p.m.

Agenda Items:

1. Updates from the Chair – Christiane Wobus

Dr. Wobus welcomed members and thanked them for attending this in-person meeting.

Dr. Wobus acknowledged Jackie Shields for 30 years of service with the IBC and thanked her for her commitment to U-M and the IBC program.

2. Consideration of minutes from the previous meeting

The committee reviewed the minutes from the December 19, 2025, meeting. There were no changes recommended.

> **Motion:** Chris Fenno moved to approve the minutes.
> **Second:** Patrick Lester seconded the motion.
> **Vote:** All in favor.

3. Biosafety Officer Report – Janet Follo

Ms. Follo stated that no incidents or injuries this month required NIH reporting

Ms. Follo reminded members the new platform for CDC Permits starts next week. Communication has gone out to all impacted persons. The CDC is still holding training sessions for its use.

4. Conflict of interest disclosure opportunity

Dr. Wobus asked committee members whether they or their labs were involved with, or were in conflict with, financially or otherwise, any items on today's agenda.

1. Patrick Lester indicated a conflict with application I IBCA00002160_AR03 for Dr. Myers.
2. Dan Lawrence indicated a conflict with application IBCA00000547_AR06 for Dr. Antonetti.

5. Applications for committee action

BSL2 Applications

The following BSL2 applications were considered and voted upon separately by the committee due to a conflict of interest.

7. IBCA00000547_AR06
Antonetti, David – Renewal
Current approval: BSL1 (plasmid and AAV vectors); BSL2 (lentivirus vectors; AAV vectors and plasmid vectors with growth control genes); BSL2 (Pertussis toxin); BSL2 (human-derived substances); BSL1 (animal-derived substances: ruminants); ABSL1 (transgenic mice and zebrafish); ABSL1 (rodents administered pertussis toxin or AAV vectors; mice administered plasmid vectors). No work involving infectious agents or plants.
Changes: No major changes.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

12. IBCA00002160_AR03
Myers Jr, Daniel – Renewal
Current approval: BSL2 (animal-derived substances from sheep and non-human primates). No work involving rDNA, infectious agents, biological toxins, human-derived substances, animals, or plants.
Changes: Added work with animal-derived substances from swine (BSL2).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

> **Motion:** Tom Lanigan moved to approve the (2) applications listed above, at the containment levels agreed upon, contingent on satisfactory completion of a laboratory inspection in the past year and upon any other contingencies noted above.
> **Second:** Matt Chapman seconded the motion.
> **Vote:** All in favor, with Patrick Lester and Dan Lawrence recused.

The following BSL2 applications were considered by the committee and voted upon:

1. IBCA00000096_AR12
Knight, Jason – Renewal
Current approval: BSL1 (AAV vectors); BSL2 (RG2 bacteria); BSL2 (LPS and Pertussis toxin); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered LPS, Pertussis toxin, AAV vectors, or human blood/blood products); ABSL2 for the duration (mice administered Klebsiella pneumoniae). No work involving animal-derived substances or plants.
Changes: No major changes.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1

and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

2. IBCA00000138_AR07
Shavit, Jordan – Amendment
Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (Klebsiella pneumoniae); BSL2 (LPS); BSL2 (human-derived substances); ABSL1 (transgenic mice and zebrafish); ABSL1 (zebrafish administered LPS); ABSL2 for the duration (zebrafish administered Klebsiella pneumoniae). No work involving animal-derived substances or plants.
Changes: Updated risk mitigation practices to propose administering Klebsiella pneumoniae to zebrafish outside of a biosafety cabinet.
Consensus: The committee agreed with the reviewers that the described BSL2 risk mitigation practices are appropriate. Approval is contingent upon minor edits being made to the application and favorable re-review by one reviewer.

3. IBCA00000214_AR09
Todd, Peter – Renewal
Current approval: BSL1 (vectorless systems, plasmid and AAV vectors); BSL2 (lentiviral vectors); BSL2 (human- and animal-derived substances from non-human primates); ABSL1 (transgenic mice and fruit flies); ABSL1 (mice administered AAV vectors or vectorless systems). No work involving infectious agents, biological toxins, or plants.
Changes: Added additional plasmid vectors (BSL1) and changed AAV vectors with toxic gene products to BSL2 and ABSL2 for 3 days.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

4. IBCA00000338_AR06
Morgan, Todd – Renewal
Current approval: BSL2 (human-derived substances). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, animals or plants.
Changes: Updated risk mitigation practices.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

5. IBCA00000480_AR04
Beamish, Jeffrey – Renewal
Current approval: BSL1 (plasmid vectors); BSL2 (lentivirus vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered rDNA modified animal cells). No work involving infectious agents, biological toxins, animal-derived substances, or plants.
Changes: Added new gene elements in plasmid vectors (BSL1) and lentivirus vectors (BSL2) and work with vectorless systems (BSL1) and MSCV vectors (BSL2) and additional human-derived substances (BSL2). Updated risk mitigation practices (BSL2). No longer administering biological substances to animals.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

6. IBCA00000538_AR08
Isom, Lori – Renewal
Current approval: BSL1 (plasmid and AAV vectors; vectorless systems); BSL2 (adenovirus, lentivirus, and MoLV vectors); BSL2 (Saxitoxin and tetrodotoxin); BSL2 (human-derived substances); ABSL1 (transgenic mice and rabbits); ABSL1 (mice and rabbits administered AAV vectors or vectorless systems); ABSL2 for 3 days (mice administered retrovirus vectors). No work involving infectious agents, animal-derived substances, or plants.
Changes: Added administration of rDNA modified animal cells to rabbits (ABSL1) and updated risk mitigation practices. Removed administration of retrovirus vectors to mice.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

7. *This application was handled separately due to a conflict of interest*.

8. IBCA00000555_AR19
Moore, Bethany – Renewal
Current approval: BSL1 (plasmid vectors); BSL2 (MoLV vectors and recombinant murine gammaherpes virus); BSL1 (RG1 viruses and bacteria); BSL2 (RG2 bacteria, fungi, and viruses; wild type Murine Roseolovirus); BSL2 (LPS and Diphtheria toxin); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered RG1 bacteria, heat-killed MRSA, LPS or Diphtheria toxin); ABSL2 for 3 days (mice administered rDNA-modified animal cells); ABSL2 for the duration (mice administered RG1 and RG2 viruses, bacteria, or fungi). No work involving animal-derived substances or plants.
Changes: Added work with Lactobacillus murinus (BSL1) with administration to mice (ABSL1).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

9. IBCA00000972_AR09
Burgess, Christian – Amendment
Current approval: BSL1 (canine adenovirus vectors and AAV vectors); BSL2 (rabies virus vectors); BSL1 (cholera toxin subunit B); ABSL1 (transgenic mice); ABSL1 (mice administered cholera toxin subunit B, rabies virus vectors, AAV vectors, or canine adenovirus vectors). No work involving infectious agents, human- or animal-derived substances, or plants.
Changes: Added new gene elements in AAV vectors (BSL2). Approval is contingent upon minor edits being made to the application.

10. IBCA00001396_AR02
Kachman, Maureen - Metabolomics Core – Renewal
Current approval: BSL2 (human-derived substances). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, animals or plants.
Changes: No major changes.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon favorable review by one reviewer.

11. IBCA00001626_AR08
Angeles, Christina – Renewal

Current approval: BSL1 (plasmid and AAV vectors); BSL2 (lentivirus vectors); BSL2 (Diphtheria toxin); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered AAV vectors, Diphtheria toxin, or rDNA modified animal cells); ABSL2 for the duration (mice administered rDNA modified human-derived substances). No work involving infectious agents, animal-derived substances, or plants.
Changes: No major changes.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

12. *This application was handled separately due to a conflict of interest*.

13. IBCA00002273_AR01
Vander Roest, Alison – Renewal
Current approval: BSL1 (plasmid vectors); BSL2 (lentiviral vectors); BSL2 (human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, animals or plants.
Changes: No major changes.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

14. IBCA00002307_AR08
Cornett, Ashley – Renewal
Current approval: BSL2 (human-derived substances); BSL1 (animal-derived substances: swine); BSL2 (animal-derived substances: sheep); ABSL1 (transgenic mice). No work involving rDNA, infectious agents, biological toxins, or plants.
Changes: Changed biosafety level of work with animal-derived substances from swine to BSL2 and added work with animal-derived substances from cows (BSL2).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

15. IBCA00003013_AR01
Shin, Jae Won – Amendment
Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentiviral vectors); BSL2 (LPS); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered vectorless systems, rDNA-modified animal cells, or LPS). No work involving infectious agents, animal-derived substances, or plants.
Changes: Added new gene elements in plasmid vectors (BSL1).
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. Approval is contingent upon minor edits being made to the application.

16. IBCA00003108
McCormick, Lauren - Initial Application
Proposed: BSL1 (plasmid and baculovirus vectors); BSL2 (human-derived substances); BSL1 (animal-derived substances: chicken). No work involving infectious agents, biological toxins, animals or plants.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon minor edits being made to the application.

Motion: Tom Lanigan motioned to approve the (14) IBC applications listed above at the containment levels agreed upon, contingent on satisfactory completion of a laboratory inspection in the past year and upon any other contingencies noted above.
Second: Matt Chapman seconded the motion.
Vote: All in favor.

BSL1 Applications

The following BSL1 applications were considered by the committee and voted upon.

17. IBCA00003103
Gordon, Amie - Initial Application
Proposed: BSL1 (human-derived substances). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, animals or plants.
Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. Approval is contingent upon minor edits being made to the application.

18. IBCA00002344_AR01
Draelos, Anne – Renewal
Current approval: ABSL1 (transgenic zebrafish). No work involving rDNA, infectious agents, biological toxins, human- or animal-derived substances, or plants.
Changes: No major changes.

Motion: Tom Lanigan motioned to approve the (2) IBC applications listed above at the containment levels agreed upon.
Second: Matt Chapman seconded the motion.
Vote: All in favor

6. Discussion Items

Item 1. Human Gene Transfer Application – Andrew Tai

HUM00283063
PI: Monalisa Ghosh
Title: A Phase 1b, Open-label, Multi-cohort Study of AZD0120, an autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cell, in Adults with Autoimmune Diseases
Sponsor: AstraZeneca

Andrew Tai described the study for the committee. He and Krishna Rao have reviewed the current submission and express support for approval of this trial. Dr. Tai noted in his review that this is an open-label clinical trial of a dual-targeting CAR-T cell therapy for adults with one of three autoimmune diseases: refractory, progressive, moderate-severe systemic sclerosis or idiopathic inflammatory myopathies, or 'difficult-to-treat' rheumatoid arthritis. Standard-of-care immunosuppressants can have significant side effects, and many patients do not achieve adequate disease control. The study agent is an autologous CAR-T cell product. The CAR is directed against both CD19 and BCMA, antigens expressed on B cells. The study agent has been used in other ongoing clinical trials, so this is not a FIH study. Observed AEs include cytopenias, fever, cytokine release syndrome, and one case of ICANS. Other potential AEs include immune effector cell-associated HLH-like syndrome, genotoxicity and malignancy,

hypogammaglobulinemia, infusion-related and hypersensitivity reactions, replication-competent lentivirus. Another AE that has been associated with BCMA-targeting CAR-T cells products is immune effector cell-associated enterocolitis.

> **Motion:** Tom Lanigan moved to approve the human gene transfer application at BSL2 containment.
> **Second:** Matt Chapman seconded the motion.
> **Vote:** All in favor.

7. Matters Arising

The EHS Research & Academic Safety Fair is scheduled for February 10, 2026, from 9:00 a.m. to 2:00 p.m. The event will take place at the Michigan League. There are several scheduled speakers throughout the day, VR testing opportunities will be available. There will be multiple vendors on site with lots of food and prizes. All are encouraged to attend.